Total Testosterone: What This Test Actually Measures in Women

What Total Testosterone Actually Measures

Total testosterone is the sum of all testosterone in your blood: the portion bound tightly to sex hormone-binding globulin (SHBG), the portion loosely bound to albumin, and the small free fraction that enters cells directly. A single number on your lab report captures all three pools together.

That sounds straightforward, but the number is harder to interpret than it looks. Most standard immunoassay methods were designed and validated against male blood samples, where testosterone concentrations run roughly 300 to 1,000 ng/dL. Women's levels generally fall between 15 and 70 ng/dL, a range where many immunoassays lose accuracy. The Endocrine Society's 2010 clinical practice guideline on androgen therapy in women stated plainly that existing assays are often unreliable at the low concentrations found in female patients, a problem that still hasn't been fully solved in routine clinical labs.

Bound vs. Free Testosterone: Why the Split Matters

About 44% of your total testosterone is tightly bound to SHBG and essentially inactive. Another 54% is loosely bound to albumin and considered bioavailable. Only roughly 1 to 2% circulates as free testosterone, the fraction your cells actually use. When your SHBG rises, as it does with oral contraceptives, thyroid disorders, or pregnancy, your total testosterone can appear normal while your bioavailable fraction drops significantly. The reverse happens when SHBG falls, as it can with insulin resistance or hypothyroidism.

Why the Assay Method Changes Everything

Liquid chromatography-tandem mass spectrometry (LC-MS/MS) is the most accurate method for measuring testosterone at low concentrations. If your result was run on a standard immunoassay and comes back at 20 or 25 ng/dL, the number may be meaningfully off. Ask your clinician which method your lab uses. The Endocrine Society recommends LC-MS/MS for women whenever androgen disorders are being evaluated.

Normal Total Testosterone Ranges for Women Across Life Stages

There is no single "normal" that applies to every woman at every age. Reference ranges differ by lab, by assay, and by where you are in your reproductive life.

Reproductive Years (Ages 18 to ~47)

Most labs report a reference interval of 15 to 70 ng/dL for premenopausal adult women, though some extend the upper limit to 80 ng/dL. Within this range, your level naturally oscillates across the menstrual cycle. Testosterone peaks around ovulation, driven by the LH surge, and is lowest in the early follicular phase. A result drawn on day 2 and a result drawn on day 14 from the same woman can differ by 20 to 30%.

Trying to Conceive

If you're trying to conceive, your clinician may order total testosterone as part of a broader androgen panel, especially if your cycles are irregular. Elevated levels can indicate anovulation from PCOS. ASRM's 2023 evidence review on PCOS diagnosis identifies biochemical hyperandrogenism, typically measured by total or free testosterone, as one of the three Rotterdam criteria used to diagnose the condition.

Pregnancy

Testosterone rises during a healthy pregnancy, particularly in the second and third trimesters, because the placenta produces androgens that are converted to estradiol. Total testosterone can reach levels of 100 to 200 ng/dL in the third trimester and still be physiologically normal. Ordering this test during pregnancy requires extra interpretive caution; a number that looks elevated outside of pregnancy may be expected during it.

Perimenopause (Roughly Ages 45 to 55)

The perimenopausal years are hormonally turbulent, with estrogen fluctuating wildly before declining, but testosterone actually follows a quieter decline that begins in your 30s. Testosterone falls by approximately 50% between ages 20 and 45, and the drop continues through perimenopause, though the rate slows after the final menstrual period.

Post-Menopause

After menopause, ovarian androgen production falls further. However, the adrenal glands continue producing androstenedione, a precursor that peripheral tissues convert to testosterone. Total testosterone in post-menopausal women typically runs between 7 and 40 ng/dL, though this varies widely and some labs do not separate their premenopausal and post-menopausal reference intervals. The Menopause Society (formerly NAMS) 2022 position statement on hormone therapy notes that testosterone measurement in this population carries added uncertainty because current assays were not designed for the very low concentrations typical after surgical or natural menopause.

What a High Total Testosterone Means for Women

A total testosterone above 70 to 80 ng/dL in a premenopausal woman, confirmed on repeat testing and using a reliable assay, is worth investigating. The clinical picture matters as much as the number.

PCOS: The Most Common Cause

Polycystic ovary syndrome affects approximately 6 to 15% of women of reproductive age and is the single most common cause of elevated testosterone in women. The elevation is usually modest, often in the 60 to 100 ng/dL range, and reflects increased ovarian androgen production driven by excess LH signaling and insulin resistance. If your testosterone is elevated and you have irregular cycles or signs of androgen excess (acne, hair thinning at the crown, facial hair), PCOS is the first diagnosis to rule in or out.

Congenital Adrenal Hyperplasia (Late-Onset)

Non-classic congenital adrenal hyperplasia (CAH) from 21-hydroxylase deficiency can mimic PCOS clinically, producing elevated androgens and menstrual irregularity. It accounts for approximately 1 to 10% of women presenting with hyperandrogenism, depending on the population. A morning 17-hydroxyprogesterone level can help distinguish it from PCOS.

Androgen-Secreting Tumors: Rare but Serious

A rapidly rising testosterone, particularly a level above 150 to 200 ng/dL, should prompt evaluation for an androgen-secreting ovarian or adrenal tumor. These are rare, but the clinical significance of missing one is high. ACOG recommends imaging when testosterone is markedly elevated and the clinical picture doesn't fit PCOS.

Other Causes Worth Considering

Exogenous androgen use (including DHEA supplements, which are converted to testosterone), insulin resistance, and Cushing syndrome can all push total testosterone above the reference range. Some medications, including certain antiepileptics, also alter SHBG and change the total-to-free ratio.

What a Low Total Testosterone Means for Women

Low testosterone in women is a murkier clinical area than high testosterone. There is no universally agreed lower threshold for female androgen insufficiency, and no FDA-approved testosterone product for women in the United States as of 2025.

Low Testosterone in Reproductive-Age Women

A level below 15 ng/dL in a premenopausal woman may be associated with reduced libido, fatigue, and diminished sense of wellbeing, but these symptoms are non-specific and many other conditions produce the same picture. Hypopituitarism, adrenal insufficiency, and oophorectomy are the conditions most consistently linked to clinically meaningful low testosterone in younger women.

Oral Contraceptives and SHBG

Combined oral contraceptives raise SHBG substantially, sometimes tripling baseline levels. This can suppress total testosterone somewhat, but more significantly drives free testosterone very low even when total appears normal. A woman experiencing low libido on the pill may have a normal total testosterone with a markedly suppressed free fraction. A 2006 study in the Journal of Sexual Medicine found that SHBG remained elevated for months after stopping oral contraceptives in some women, a phenomenon sometimes called "post-pill SHBG elevation."

Post-Menopausal Low Testosterone and Sexual Function

Hypoactive sexual desire disorder (HSDD) affects an estimated 40% of women after menopause and is the condition for which the evidence for testosterone therapy is strongest. The Global Consensus Position Statement on the Use of Testosterone Therapy for Women (2019), co-endorsed by The Menopause Society, concluded that there is Level 1 evidence supporting testosterone use for HSDD in post-menopausal women. Measuring baseline total testosterone before starting treatment, and monitoring levels during therapy, is standard practice, even though a low level alone does not diagnose HSDD.

How Your Menstrual Cycle and Hormonal Status Change the Result

Most lab reference sheets don't tell you which cycle day to draw your sample. Here is what actually matters for interpreting your result as a woman:

Follicular phase (days 1 to 13): Testosterone is at or near its monthly low. A result in this window may underestimate your average level.

Ovulatory phase (days 12 to 16): The LH surge drives a transient spike in testosterone, sometimes 20 to 40% above follicular baseline. This is the physiological peak.

Luteal phase (days 15 to 28): Levels are intermediate and relatively stable.

Recommendation: For the most clinically useful snapshot, draw blood in the morning on days 8 to 20 of your cycle if your cycles are regular. The Endocrine Society guideline does not mandate a specific cycle day but acknowledges that timing affects interpretation.

Hormonal contraception: Combined pills suppress LH and FSH, which reduces ovarian testosterone production and raises SHBG. Both effects push total testosterone toward the lower end of the normal range or below it. Progestin-only methods and hormonal IUDs generally have less impact on total testosterone than combined pills.

Postpartum and lactation: Prolactin, which rises substantially during breastfeeding, suppresses the HPG axis. Testosterone may remain low for weeks to months postpartum, particularly in exclusively breastfeeding women. Testing during active lactation requires cautious interpretation.

PCOS, Androgen-Related Conditions, and Total Testosterone

Women with PCOS represent the largest group for whom total testosterone testing is clinically actionable in the reproductive years. But several other female-specific conditions intersect with androgen levels in ways that aren't always discussed.

Female pattern hair loss (androgenic alopecia): Many women with this condition have total testosterone within the normal range. The issue is often increased sensitivity of hair follicles to dihydrotestosterone (DHT) rather than elevated circulating levels. Testing is still recommended to rule out a treatable cause.

Hormonal acne: Similar to hair loss, androgen-sensitive acne in adult women often occurs with normal total testosterone. Free testosterone or DHEA-S may be more revealing. If your acne is cyclically worse and accompanied by irregular periods, a full androgen panel is worth running.

Endometriosis: The relationship between androgens and endometriosis is complex and still being studied. Some research suggests lower androgen levels may be associated with higher disease burden, but this area lacks the strong clinical trial data needed for firm recommendations. A 2021 review in Human Reproduction Update noted that women with endometriosis had lower total testosterone on average compared to controls, though causality remains unclear.

Thyroid disorders: Hypothyroidism lowers SHBG, which can raise free testosterone even when total stays the same. Hyperthyroidism raises SHBG, suppressing free testosterone. If your testosterone result doesn't fit your symptoms, thyroid function should be checked.

Osteoporosis: Testosterone contributes to bone mineral density in women, partly through conversion to estradiol and partly through direct androgenic effects on bone. Women with premature ovarian insufficiency (POI), who lose both estrogen and testosterone earlier than typical, face higher fracture risk and may benefit from testosterone monitoring as part of bone health management.

How to Raise or Lower Total Testosterone: What the Evidence Supports

This is the area where social media diverges most sharply from clinical evidence. Here is what is actually supported.

Raising Low Testosterone

No FDA-approved testosterone formulation exists specifically for women in the United States. Clinicians who prescribe testosterone for women typically use off-label compounded preparations or male-labeled testosterone products at female doses (generally one-tenth of male doses). The Global Consensus Position Statement (2019) supports this approach specifically for post-menopausal women with HSDD, using physiological doses that maintain serum levels in the normal premenopausal female range.

Lifestyle factors that may support testosterone in the lower end of the normal range include resistance training, adequate sleep, and maintaining a healthy body weight. No supplement has strong clinical trial evidence for raising testosterone meaningfully in women at physiological doses.

Lowering High Testosterone

For women with PCOS, the following approaches have documented evidence:

Combined oral contraceptives: Reduce testosterone by suppressing LH-driven ovarian production and raising SHBG. This remains the first-line medical treatment for hyperandrogenism in PCOS per ACOG Practice Bulletin 194.

Metformin: Reduces insulin-driven androgen production in PCOS, though its effect on total testosterone is more modest than its effect on insulin and LH. A Cochrane review (2012) found that metformin improved menstrual frequency in PCOS but had variable effects on total testosterone depending on dose and duration.

Spironolactone: An antiandrogen that competes with DHT at the receptor level and modestly suppresses adrenal androgen production. Often used off-label for PCOS-related acne and hirsutism. A 2017 systematic review in the Journal of the American Academy of Dermatology found spironolactone at 100 to 200 mg/day significantly improved acne in women with or without elevated total testosterone.

Weight loss: In women with PCOS and overweight, a 5 to 10% reduction in body weight can meaningfully reduce testosterone by decreasing insulin resistance and LH pulse amplitude.

Pregnancy and Lactation: What to Know Before Testing

This section is required because decisions about androgen testing and treatment have direct implications for women who are pregnant, planning pregnancy, or breastfeeding.

Testosterone testing in pregnancy: Normal total testosterone rises across pregnancy. A value that looks high outside pregnancy may be expected within it. If an androgen-secreting tumor is suspected in pregnancy, MRI without gadolinium is the preferred imaging method. Adrenal tumors have been reported in pregnancy and require specialist management.

Testosterone therapy in pregnancy: Contraindicated. Exogenous testosterone can virilize a female fetus. Any woman on testosterone therapy who might become pregnant needs reliable contraception. Pregnancy testing before initiating treatment and strong contraception counseling are non-negotiable. The Global Consensus Position Statement (2019) states this explicitly and limits evidence-based use to post-menopausal women.

Lactation: Testosterone transfer into breast milk does occur. Data on the magnitude and clinical significance for nursing infants are limited. The LactMed database (NIH) notes that exogenous testosterone should be used with caution during lactation given insufficient safety data. Most clinicians advise against testosterone therapy while breastfeeding.

Spironolactone and pregnancy: Spironolactone is teratogenic in animal models, with potential for feminization of male fetuses. It should not be used in pregnancy. Women of reproductive age using spironolactone for PCOS-related hyperandrogenism need concurrent reliable contraception.

Who This Test Is Right For, and Who Should Wait

Good candidates for a total testosterone test:

• Women with irregular cycles and signs of androgen excess (acne, hirsutism, scalp hair thinning)
• Women being evaluated for PCOS under Rotterdam criteria
• Post-menopausal women with HSDD being considered for off-label testosterone therapy
• Women with suspected adrenal or ovarian pathology
• Women on testosterone therapy requiring monitoring to keep levels in physiologic range
• Women with premature ovarian insufficiency being managed for bone health and wellbeing

Women who should interpret results cautiously:

• Women on combined oral contraceptives (total level will be suppressed; free testosterone tells more)
• Pregnant women (expected rise in total testosterone)
• Breastfeeding women (axis suppressed by prolactin)
• Women whose sample was drawn on standard immunoassay at a general commercial lab (request LC-MS/MS confirmation if results guide treatment decisions)

Testing alone is not enough. Total testosterone should almost never be ordered or interpreted in isolation. A complete androgen panel includes free testosterone (or calculated free testosterone from SHBG and albumin), DHEA-S, SHBG, and often LH, FSH, and prolactin, depending on the clinical picture.

Reading Your Lab Report: A Practical Guide

Lab reports differ in layout and reference ranges, which creates unnecessary confusion. Here is how to read yours:

Step 1: Confirm the reference range printed on your report applies to your sex and age group. Some labs use a combined adult range that defaults to male values.

Step 2: Check which assay method was used. Look for "immunoassay" vs. "LC-MS/MS" or "mass spec" in the methodology notes. If you can't find it, call the lab and ask.

Step 3: Note what day of your cycle the sample was collected and whether you were fasting. Morning samples, collected between 7 and 10 a.m., reflect the daily testosterone peak and are preferred for comparability.

Step 4: Compare your result to the life-stage context, not just the printed range. A result of 65 ng/dL in a post-menopausal woman means something very different than the same result in a 28-year-old with regular cycles.

Step 5: Repeat before acting. A single abnormal result in an asymptomatic woman rarely warrants treatment. The Endocrine Society guideline recommends confirming any significant elevation or suppression with a second sample, drawn under standardized conditions, before making clinical decisions.